Clinical trials: Endometrial Cancer Stage II
Endometrial Cancer
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer
RATIONALE: Estrogen can stimulate the growth of endometrial cancer cells. Hormone therapy using arzoxifene hydrochloride may fight the endometrial cancer by blocking the use of estrogen by the tumor cells PURPOSE: This phase II…
- Trial name
- NCT00003669
- Testing
- arzoxifene hydrochloride
- Where
- 10 sites in United States
- Sponsor
- Eli Lilly and Company
Recurrent Endometrial Carcinoma
Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290
This trial assesses blood and tumor samples for the effect of trametinib with or without uprosertib on biomarkers in patients enrolled on trial GOG02290 with endometrial cancer that is persistent or has come back.
- Trial name
- NCT02093546
- Testing
- Biospecimen Collection
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Cancer, Gastrointestinal Complications
Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06
Post-operative radiotherapy is internationally accepted as standard practice in the management of high-risk endometrial cancer1. Whilst it has no proven impact on overall survival it significantly increases local control.
- Conditions
- Endometrial Cancer, Gastrointestinal Complications, Radiation Toxicity, Urinary Complications
- Trial name
- NCT01164150
- Testing
- 45 Gy/25 fractions
- Where
- 5 sites in Ireland
- Volunteers
- 92 people
- Sponsor
- Cancer Trials Ireland
Mesenchymal Tumor, Carcinosarcoma
Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors
Uterine sarcomas account for less than 5% of all carcinomas of the uterine corpus. The prognosis of these patients is extremely limited. Recurrence rates of 50-60% are reported even for early-stage disease (FIGO I/II).
- Conditions
- Mesenchymal Tumor, Carcinosarcoma, Leiomyosarcoma
- Trial name
- NCT00815945
- Testing
- PegLiposomal Doxorubicin, Carboplatin
- Where
- 15 sites in Germany
- Volunteers
- 41 people
- Sponsor
- AGO Study Group
Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma
Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
This phase I trial is studying the side effects and best dose of cisplatin given together with paclitaxel in treating patients with stage IIB, stage IIC, stage III, or stage IV ovarian epithelial cancer, fallopian tube cancer, or…
- Conditions
- Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma, Fallopian Tube Carcinoma, Gastrointestinal Complication
- Trial name
- NCT00814086
- Testing
- Paclitaxel, Cisplatin
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Gynecologic Oncology Group
Advanced Cancer, Advanced Solid Tumor
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
This study is an open-label, multi-arm, parallel cohort, dose validation and expansion design. The study is modular in design, allowing evaluation of the safety, efficacy and pharmacokinetics (PK) of NUC-3373 in combination with…
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer
- Trial name
- NCT05714553
- Testing
- Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- NuCana plc
Endometrial Cancer
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
The primary objective of this study is to estimate whether the addition of trastuzumab to paclitaxel and carboplatin chemotherapy improves progression free survival when compared to paclitaxel and carboplatin alone in Uterine…
- Trial name
- NCT01367002
- Testing
- Carboplatin/Paclitaxel, Trastuzumab
- Where
- 20 sites in United States
- Volunteers
- 61 people
- Sponsor
- Yale University
Endometrial Cancer
Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of letrozole in treating women who have recurrent or…
- Trial name
- NCT00004251
- Testing
- letrozole
- Volunteers
- 33 people
- Sponsor
- NCIC Clinical Trials Group
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
This randomized phase II trial studies paclitaxel, carboplatin, and bevacizumab or paclitaxel, carboplatin, and temsirolimus or ixabepilone, carboplatin, and bevacizumab to see how well they work in treating patients with stage…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma
- Trial name
- NCT00977574
- Testing
- Bevacizumab, Carboplatin, Ixabepilone
- Where
- 230 sites in United States
- Volunteers
- 349 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer
Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer
RATIONALE: Ridaforolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00770185
- Testing
- ridaforolimus, gene expression analysis, immunohistochemistry staining method
- Where
- 11 sites in Canada
- Volunteers
- 35 people
- Sponsor
- NCIC Clinical Trials Group
Endometrial Cancer, Ovarian Cancer
Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have advanced…
- Conditions
- Endometrial Cancer, Ovarian Cancer, Sarcoma
- Trial name
- NCT00003718
- Testing
- temozolomide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Endometrial Cancer
Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus II
Adjuvant radiotherapy (RT) plays an important role in reducing the risks of local recurrence after surgery in uterine cancers. Standard adjuvant pelvic radiation treatment targets the pelvic lymph nodes, the post-operative bed…
- Trial name
- SPARTACUSII (NCT04890912)
- Testing
- Conventional Fractionation, Hypofractionation
- Where
- 5 sites in Canada
- Volunteers
- 50 people
- Sponsor
- Sunnybrook Health Sciences Centre
Cervical Cancer, Endometrial Cancer
Pelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal Cancer
RATIONALE: The use of pelvic drains may help to prevent complications following radical hysterectomy and pelvic lymphadenectomy.
- Conditions
- Cervical Cancer, Endometrial Cancer, Infection, Perioperative/Postoperative Complications
- Trial name
- NCT00003267
- Testing
- infection prophylaxis and management, management of therapy complications, surgical procedure
- Where
- 18 sites in Austria, Belgium and 6 more
- Volunteers
- 214 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT05112601
- Testing
- Biospecimen Collection, Computed Tomography, Ipilimumab
- Where
- 138 sites in United States
- Volunteers
- 81 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Neoplasms, Neoplasm Recurrence, Local
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of cadonilimab in combination with paclitaxel, cisplatin, and radiation therapy for the treatment of locally recurrent and oligometastatic endometrial…
- Conditions
- Endometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis
- Trial name
- NCT06532539
- Testing
- Paclitaxel and Cisplatin, Cadonilimab, Radiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shandong Cancer Hospital and Institute
Ovarian Carcinosarcoma, Endometrial Carcinosarcoma
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
Carcinosarcomas (CS) (malignant mixed Müllerian tumors) are highly aggressive and rare tumors with a worldwide annual incidence between 0.5-3.3 cases/100.000 women. Gynecological CS, i.e.
- Trial name
- ROCSAN (NCT03651206)
- Testing
- Niraparib, Niraparib + TSR-042 (Dostarlimab), Chemotherapy Drugs
- Where
- 36 sites in France, Italy and 1 more
- Volunteers
- 138 people
- Sponsor
- ARCAGY/ GINECO GROUP
Endometrial Cancer, Papillary Serous
Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
The purpose of this study is to determine the progression-free survival of patients with surgically staged, Stage I-II papillary serous, clear cell, or endometrioid carcinomas with high-intermediate risk factors treated by…
- Conditions
- Endometrial Cancer, Papillary Serous, Clear Cell Endometrial Cancer
- Trial name
- NCT00542490
- Testing
- Vaginal Cuff Brachytherapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Oklahoma
Endometrial Cancer Stage I, Endometrial Cancer Stage II
Cost-utility of Ambulatory Surgery in the Management of Endometrial Cancer(AMBU-ENDO)
To date, cost-utility, safety, and feasibility of ambulatory surgery versus traditional pathway in the management of endometrial cancer have never been prospectively assessed.
- Trial name
- AMBU-ENDO (NCT03580421)
- Testing
- ambulatory surgery, standard surgery
- Where
- 9 sites in France
- Volunteers
- 77 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Endometrial Cancer
END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin
The purpose of this study is to evaluate activity and toxicity of the combination of carboplatin and liposomal doxorubicin as first-line chemotherapy of patients with advanced or recurrent endometrial carcinoma.
- Trial name
- NCT00401635
- Testing
- liposomal doxorubicin, carboplatin
- Where
- 4 sites in Italy
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute, Naples
Ovarian Carcinoma, Endometrial Carcinoma
Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies
The primary trial objective is to determine the efficacy of KPT-330 (selinexor) in participants with advanced or metastatic gynaecological cancers by disease control rate (complete response (CR) or partial response (PR) or stable…
- Conditions
- Ovarian Carcinoma, Endometrial Carcinoma, Cervical Carcinoma
- Trial name
- SIGN (NCT02025985)
- Testing
- Selinexor
- Where
- 4 sites in Belgium, Denmark
- Volunteers
- 116 people
- Sponsor
- Karyopharm Therapeutics Inc